CHMA - Chiasma highlights benefit of Mycapssa with new data in acromegaly

Announcing new positive clinical data from its MPOWERED™ Phase 3 trial, Chiasma (CHMA) says MYCAPSSA has improved clinical symptoms and other patient-reported outcomes compared to long-acting injectable somatostatin receptor ligands (iSRLs) in patients with acromegaly.In the maintenance of biochemical response, MYCAPSSA has also met the pre-specified non-inferiority margin compared to long-acting iSRLs.91% (CI, 80%-97%) of the MYCAPSSA patients have maintained insulin-like growth factor 1 (IGF-1) response during the randomized controlled treatment (RCT"") phase.From the baseline (time of the first dose of MYCAPSSA in run-in), a statistically significant (p = 0.001) decline was noted in the number of active acromegaly symptoms.“I believe that these data provide valuable insights to physicians on the potential benefit of a twice daily oral drug versus long-acting injections for most patients,” said Maria Fleseriu, a professor of Medicine and Neurological Surgery and the lead investigator of the study.In November 2020, Chiasma announced positive top-line data for Mycapssa

For further details see:

Chiasma highlights benefit of Mycapssa with new data in acromegaly